Cost–effectiveness of lung cancer screening with volume computed tomography in Portugal

2024-9-27

A clinical decision support tool for metabolic dysfunction-associated steatohepatitis in real-world clinical settings: a mixed-method implementation research study protocol

2024-9-20

A systematic review of health-related quality of life outcomes in patients with advanced breast cancer treated with palbociclib

2024-9-17

Comparing the efficacy of cipaglucosidase alfa plus miglustat with other enzyme replacement therapies for late-onset Pompe disease: a network meta-analysis utilizing patient-level and aggregate data

2024-9-17

Why is the market design for innovative pharmaceuticals not well understood?

2024-9-10

How pharma can amplify product value with implementation science

2024-9-6

One-year budget impact of InTandem™: a novel neurorehabilitation system for individuals with chronic stroke walking impairment

2024-9-3

Comparative efficacy of diroximel fumarate, ozanimod and interferon beta-1a for relapsing multiple sclerosis using matching-adjusted indirect comparisons

2024-8-19

Lessons on the use of real-world data in medical device research: findings from the National Evaluation System for Health Technology Test-Cases

2024-8-16

A matching-adjusted indirect comparison of centanafadine versus lisdexamfetamine, methylphenidate and atomoxetine in adults with attention-deficit/hyperactivity disorder: long-term safety and efficacy

2024-8-12

The maze of real-world evidence frameworks: from a desert to a jungle! An environmental scan and comparison across regulatory and health technology assessment agencies

2024-8-12

An international observational study assessing conservative management in hemorrhoidal disease: results of CHORALIS (aCute HemORrhoidal disease evALuation International Study)

2024-8-12

Patient-reported preferences for subcutaneous or intravenous administration of parenteral drug treatments in adults with immune disorders: a systematic review and meta-analysis

2024-8-8

Corrigendum

2024-8-2

Improvements in daytime sleepiness and disrupted nighttime sleep with once-nightly sodium oxybate in people with narcolepsy type 1 and type 2: a plain language summary

2024-8-1

COVID-19 clinical trials: who is likely to participate and why?

2024-7-24

Val (EU) xit: do we need an international ISPOR value flower?

2024-7-19

Serious treatment-emergent adverse events in chronic low back pain patients treated with buprenorphine or oral opioids: a retrospective commercial claims analysis

2024-7-16

A review of 25 years of National Institute of Health and Care Excellence decision making

2024-7-16

Adverse event costs of systemic therapies for metastatic colorectal cancer previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy and biologics in the US

2024-7-8

RWE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 16

2024-7-5

The value of evidence and its role in driving product strategy

2024-7-1

Evaluation of inpatient and emergency department healthcare resource utilization and costs pre- and post-nusinersen for the treatment of spinal muscular atrophy using United States claims

2024-7-1

Changes in symptom burden and quality of life among women with uterine fibroids receiving relugolix combination therapy: a plain language summary

2024-6-27

Six-minute walk test as clinical end point in cardiomyopathy clinical trials, including ATTR-CM: a systematic literature review

2024-6-13

Evaluating the robustness of an AI pathfinder application on eligibility criteria in multiple myeloma trials using real-world data and historical trials

2024-6-13

Healthcare resource utilization among nursing home residents with Parkinson's disease psychosis: an analysis of Medicare beneficiaries treated with pimavanserin or other-atypical antipsychotics

2024-6-8

Why is target trial emulation not being used in health technology assessment real-world data submissions?

2024-6-8

First in class, best in class or a wild card: who will dominate the anti-obesity medication market?

2024-5-29

A clinical systematic literature review of treatments among patients with advanced and/or metastatic human epidermal growth factor receptor 2 positive breast cancer

2024-5-29

A plain language summary of the perspectives of women who were interviewed about their experiences with uterine fibroids

2024-5-28

Comparing prospectively assigned trial and real-world lung cancer patients

2024-5-24

Progress of patients hospitalized with acute heart failure treated with empagliflozin

2024-5-24

Phosphodiesterase type 5 inhibitors as treatment for erectile dysfunction: a webinar-based poll unveiling perceptions of healthcare professionals

2024-5-22

Cost–effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure

2024-5-21

EU HTA Joint Clinical Assessment: are patients with rare disease going to lose out?

2024-5-2

Healthcare resource utilization and costs among patients with alpha-1 antitrypsin deficiency with liver and/or lung disease: a longitudinal retrospective study in the USA

2024-5-2

Cost of disease progression among US patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

2024-4-22

Access in all areas? a round up of developments in market access and health technology assessment: part 4

2024-4-22

Polymer-based drug-eluting stent treatment extends the time to reintervention for patients with symptomatic femoropopliteal artery disease: clinical evidence and potential economic value

2024-4-12

Letter in reply: network meta-analysis for indirect comparison of lanadelumab and for the treatment of hereditary angioedema

2024-4-12

Comparing the outcomes and costs of cardiac monitoring with implantable loop recorders and mobile cardiac outpatient telemetry following stroke using real-world evidence.

2024-4-11

Augmenting external control arms using Bayesian borrowing: a case study in first-line non-small cell lung cancer

2024-4-4

Assessing the performance of physician's prescribing preference as an instrumental variable in comparative effectiveness research with moderate and small sample sizes: a simulation study

2024-4-3

The impact of willingness-to-pay threshold on price reduction recommendations for oncology drugs: a review of assessments conducted by the Canadian Agency for Drugs and Technologies in Health

2024-4-3

Comparing the performance of two-stage residual inclusion methods when using physician's prescribing preference as an instrumental variable: unmeasured confounding and noncollapsibility

2024-4-3

R WE ready for reimbursement? A round up of developments in real-world evidence relating to health technology assessment: part 15

2024-3-28

Letter to the editor: network meta-analysis for indirect comparison of lanadelumab and berotralstat for the treatment of hereditary angioedema

2024-3-28

Digital variance angiography in patients undergoing lower limb arterial recanalization: cost–effectiveness analysis within the English healthcare setting

2024-3-22

Gastrointestinal adverse effects associated with the use of intravenous oliceridine compared with intravenous hydromorphone or fentanyl in acute pain management utilizing adjusted indirect treatment comparison methods

2024-3-18